Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Follow-Up Questions
Newron Pharmaceuticals SpA 的 CEO 是谁？
Prof. Stefan Weber 是 Newron Pharmaceuticals SpA 的 Chief Executive Officer，自 2005 加入公司。
NWPHF 股票的价格表现如何？
NWPHF 的当前价格为 $0，在上个交易日 decreased 了 0%。
Newron Pharmaceuticals SpA 的主要业务主题或行业是什么？
Newron Pharmaceuticals SpA 属于 Pharmaceuticals 行业，该板块是 Health Care
